INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 449m ago
HOUSE PTR49m ago
SEC 13F49m ago
ROBINHOOD CHAIN49m ago
SEC FORM 4/Option exerciseVerified data

Claypoole Robert E reported BVS

Director, President and CEO · Bioventus Inc. · Class A Common Stock

Side
M
Value
—
Shares
93.8K
Price
—
Executed
Jan 9, 2026
Disclosed
Jan 13, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 9 executedJan 13, 2026 disclosed

BVS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
21/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+13 / 25

No reported dollar value · 144.3% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BVS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    17
    MM
    McMurry-Heath MichelleDirector
    BVSBioventus Inc.
    Option exercise
    		M—
    32.3K sh
    		Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    		+2dSEC FORM 4

    Evidence

    5
    MM
    McMurry-Heath MichelleDirector
    BVSBioventus Inc.
    Grant or award
    		A—
    25.1K sh
    		Jun 3, 2026Jun 4, 2026
    traded Jun 3, 2026
    		+1dSEC FORM 4

    Evidence

    5
    MM
    McMurry-Heath MichelleDirector
    BVSBioventus Inc.
    Option exercise
    		M—
    32.3K sh
    		Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    DA
    D'Adamio AnthonySVP & General Counsel
    BVSBioventus Inc.
    Option exercise
    		M—
    9,925 sh
    		Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Option exercise
    		M—
    13.0K sh
    		Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    		+4dSEC FORM 4

    Evidence

    13
    DA
    D'Adamio AnthonySVP & General Counsel
    BVSBioventus Inc.
    Option exercise
    		M—
    9,925 sh
    		Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    		+4dSEC FORM 4

    Evidence

    9
    DA
    D'Adamio AnthonySVP & General Counsel
    BVSBioventus Inc.
    Tax withholding
    		F$39K
    4,312 sh
    		Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    		+4dSEC FORM 4

    Evidence

    12
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Tax withholding
    		F$51K
    5,648 sh
    		Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    		+4dSEC FORM 4

    Evidence

    13
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Option exercise
    		M—
    13.0K sh
    		Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    		+4dSEC FORM 4

    Evidence

    13
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Option exercise
    		M—
    18.6K sh
    		Mar 20, 2026Mar 24, 2026
    traded Mar 20, 2026
    		+4dSEC FORM 4

    Evidence

    12
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Tax withholding
    		F$70K
    8,091 sh
    		Mar 20, 2026Mar 24, 2026
    traded Mar 20, 2026
    		+4dSEC FORM 4

    Evidence

    9
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Option exercise
    		M—
    18.6K sh
    		Mar 20, 2026Mar 24, 2026
    traded Mar 20, 2026
    		+4dSEC FORM 4

    Evidence

    21
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Option exercise
    		M—
    33.5K sh
    		Mar 13, 2026Mar 17, 2026
    traded Mar 13, 2026
    		+4dSEC FORM 4

    Evidence

    24
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Grant or award
    		A—
    134.0K sh
    		Mar 14, 2025Mar 17, 2026
    traded Mar 14, 2025
    		+368dSEC FORM 4

    Evidence

    24
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Grant or award
    		A—
    153.0K sh
    		Mar 14, 2025Mar 17, 2026
    traded Mar 14, 2025
    		+368dSEC FORM 4

    Evidence

    9
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Grant or award
    		A—
    278.0K sh
    		Mar 13, 2026Mar 17, 2026
    traded Mar 13, 2026
    		+4dSEC FORM 4

    Evidence

    9
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Grant or award
    		A—
    309.0K sh
    		Mar 13, 2026Mar 17, 2026
    traded Mar 13, 2026
    		+4dSEC FORM 4

    Evidence

    17
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Option exercise
    		M—
    33.5K sh
    		Mar 13, 2026Mar 17, 2026
    traded Mar 13, 2026
    		+4dSEC FORM 4

    Evidence

    16
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Tax withholding
    		F$125K
    14.6K sh
    		Mar 13, 2026Mar 17, 2026
    traded Mar 13, 2026
    		+4dSEC FORM 4

    Evidence

    28
    MM
    McMurry-Heath MichelleDirector
    BVSBioventus Inc.
    Open-market sale
    		SELL$105K
    12.0K sh
    		Mar 11, 2026Mar 13, 2026
    traded Mar 11, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002005474-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 9, 2026
    Published
    Jan 13, 2026
    Ingested by INSIDER
    Nov 5, 04:23 UTC
    Last re-read
    Nov 5, 04:23 UTC

    Extracted facts

    Filer
    Claypoole Robert E
    Role
    Director, President and CEO
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Bioventus Inc.
    Ticker
    BVS
    Shares
    93.8K
    Price per share
    $0
    Execution date (reported)
    Jan 9, 2026
    Owned after transaction
    158.7K shares
    Days from execution to publication
    4

    What this establishes

    Claypoole Robert E filed this Form 4 reporting a option exercise of BVS on Jan 9, 2026. It became public on Jan 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, President and CEO
    Claypoole Robert Ecik:0002005474
    Issuer
    Bioventus Inc.cik:0001665988

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.